Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
7 "Renal insufficiency, chronic"
Filter
Filter
Article type
Keywords
Publication year
Authors
Funded articles
Review Articles
Diabetes, Obesity and Metabolism
Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
Endocrinol Metab. 2023;38(1):43-55.   Published online February 27, 2023
DOI: https://doi.org/10.3803/EnM.2022.1629
  • 5,131 View
  • 726 Download
  • 2 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
Chronic kidney disease (CKD) is the most common cause of end-stage renal disease in patients with type 2 diabetes mellitus (T2DM). CKD increases the risk of cardiovascular diseases; therefore, its prevention and treatment are important. The prevention of diabetic kidney disease (DKD) can be achieved through intensive glycemic control and blood pressure management. Additionally, DKD treatment aims to reduce albuminuria and improve kidney function. In patients with T2DM, renin-angiotensin-aldosterone system inhibitors, sodium glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists can delay the progression of DKD. Hence, there is a need for novel treatments that can effectively suppress DKD progression. Finerenone is a first-in-class nonsteroidal mineralocorticoid receptor antagonist with clinically proven efficacy in improving albuminuria, estimated glomerular filtration rate, and risk of cardiovascular events in early and advanced DKD. Therefore, finerenone is a promising treatment option to delay DKD progression. This article reviews the mechanism of renal effects and major clinical outcomes of finerenone in DKD.

Citations

Citations to this article as recorded by  
  • Neue Antihypertensiva im Renin-Angiotensin-Aldosteron-System
    Markus van der Giet
    CardioVasc.2024; 24(1): 33.     CrossRef
  • Epigenetic modification in diabetic kidney disease
    Zhe Liu, Jiahui Liu, Wanning Wang, Xingna An, Ling Luo, Dehai Yu, Weixia Sun
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review
    Sandra Martínez-Hernández, Martín Muñoz-Ortega, Manuel Ávila-Blanco, Mariana Medina-Pizaño, Javier Ventura-Juárez
    Biomedicines.2023; 11(10): 2828.     CrossRef
  • Finerenone and other future therapeutic options for Alport syndrome
    Helen Pearce, Holly Mabillard
    Journal of Rare Diseases.2023;[Epub]     CrossRef
Close layer
Diabetes, Obesity and Metabolism
Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond
Adie Viljoen, Stephen C. Bain
Endocrinol Metab. 2023;38(1):25-33.   Published online February 6, 2023
DOI: https://doi.org/10.3803/EnM.2022.1642
  • 2,572 View
  • 301 Download
  • 3 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   ePub   
The therapeutic benefits of the incretin hormone, glucagon-like peptide 1 (GLP1), for people with type 2 diabetes and/or obesity, are now firmly established. The evidence-base arising from head-to-head comparative effectiveness studies in people with type 2 diabetes, as well as the recommendations by professional guidelines suggest that GLP1 receptor agonists should replace more traditional treatment options such as sulfonylureas and dipeptidyl-peptidase 4 (DPP4) inhibitors. Furthermore, their benefits in reducing cardiovascular events in people with type 2 diabetes beyond improvements in glycaemic control has led to numerous clinical trials seeking to translate this benefit beyond type 2 diabetes. Following early trial results their therapeutic benefit is currently being tested in other conditions including fatty liver disease, kidney disease, and Alzheimer’s disease.

Citations

Citations to this article as recorded by  
  • The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
    Agnieszka Jakubowska, Carel W. le Roux, Adie Viljoen
    Endocrinology and Metabolism.2024; 39(1): 12.     CrossRef
  • Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
    John R. Ussher, Daniel J. Drucker
    Nature Reviews Cardiology.2023; 20(7): 463.     CrossRef
  • A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena
    Stephen C Bain, Thinzar Min
    The Lancet.2023; 402(10401): 504.     CrossRef
  • Flattening the biological age curve by improving metabolic health: to taurine or not to taurine, that’ s the question
    Kwok M. Ho, Anna Lee, William Wu, Matthew T.V. Chan, Lowell Ling, Jeffrey Lipman, Jason Roberts, Edward Litton, Gavin M. Joynt, Martin Wong
    Journal of Geriatric Cardiology.2023; 20(11): 813.     CrossRef
Close layer
Original Articles
Miscellaneous
Clinical Value of Serum Mitochondria-Inhibiting Substances in Assessing Renal Hazards: A Community-Based Prospective Study in Korea
Hoon Sung Choi, Jin Taek Kim, Hong Kyu Lee, Wook Ha Park, Youngmi Kim Pak, Sung Woo Lee
Endocrinol Metab. 2021;36(6):1298-1306.   Published online November 26, 2021
DOI: https://doi.org/10.3803/EnM.2021.1226
  • 3,144 View
  • 94 Download
  • 1 Web of Science
  • 1 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Mitochondrial dysfunction is strongly associated with several kidney diseases. However, no studies have evaluated the potential renal hazards of serum mitochondria-inhibiting substance (MIS) and aryl hydrocarbon receptor ligand (AhRL) levels.
Methods
We used serum level of MIS and AhRL and clinical renal outcomes from 1,511 participants of a prospective community-based cohort in Ansung. MIS was evaluated based on intracellular adenosine triphosphate (MIS-ATP) or reactive oxygen species (MIS-ROS) generation measured using cell-based assays.
Results
During a mean 6.9-year follow-up, 84 participants (5.6%) developed a rapid decline in kidney function. In the lowest quartile group of MIS-ATP, patients were older and had metabolically deleterious parameters. In multivariate logistic regression analysis, higher MIS-ATP was associated with decreased odds for rapid decline: the odds ratio (OR) of 1% increase was 0.977 (95% confidence interval [CI], 0.957 to 0.998; P=0.031), while higher MIS-ROS was marginally associated with increased odds for rapid decline (OR, 1.014; 95% CI, 0.999 to 1.028; P=0.055). However, serum AhRL was not associated with the rapid decline in kidney function. In subgroup analysis, the renal hazard of MIS was particularly evident in people with hypertension and low baseline kidney function.
Conclusion
Serum MIS was independently associated with a rapid decline in kidney function, while serum AhRL was not. The clinical implication of renal hazard on serum MIS requires further evaluation in future studies.

Citations

Citations to this article as recorded by  
  • An Interactive Online App for Predicting Diabetes via Machine Learning from Environment-Polluting Chemical Exposure Data
    Rosy Oh, Hong Kyu Lee, Youngmi Kim Pak, Man-Suk Oh
    International Journal of Environmental Research and Public Health.2022; 19(10): 5800.     CrossRef
Close layer
Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
Eugene Han, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Beom Seok Kim, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
Endocrinol Metab. 2017;32(2):274-280.   Published online June 23, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.2.274
  • 5,133 View
  • 173 Download
  • 8 Web of Science
  • 8 Crossref
AbstractAbstract PDFPubReader   
Background

Although the beneficial effects of statin treatment in dyslipidemia and atherosclerosis have been well studied, there is limited information regarding the renal effects of statins in diabetic nephropathy. We aimed to investigate whether, and which, statins affected renal function in Asian patients with diabetes.

Methods

We enrolled 484 patients with diabetes who received statin treatment for more than 12 months. We included patients treated with moderate-intensity dose statin treatment (atorvastatin 10 to 20 mg/day or rosuvastatin 5 to 10 mg/day). The primary outcome was a change in estimated glomerular filtration rate (eGFR) during the 12-month statin treatment, and rapid renal decline was defined as a >3% reduction in eGFR in a 1-year period.

Results

In both statin treatment groups, patients showed improved serum lipid levels and significantly reduced eGFRs (from 80.3 to 78.8 mL/min/1.73 m2 for atorvastatin [P=0.012], from 79.1 to 76.1 mL/min/1.73 m2 for rosuvastatin [P=0.001]). A more rapid eGFR decline was observed in the rosuvastatin group than in the atorvastatin group (48.7% vs. 38.6%, P=0.029). Multiple logistic regression analyses demonstrated more rapid renal function loss in the rosuvastatin group than in the atorvastatin group after adjustment for other confounding factors (odds ratio, 1.60; 95% confidence interval, 1.06 to 2.42).

Conclusion

These results suggest that a moderate-intensity dose of atorvastatin has fewer detrimental effects on renal function than that of rosuvastatin.

Citations

Citations to this article as recorded by  
  • Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial
    Chan Joo Lee, Woong Chol Kang, Sang Hyun Ihm, Il Suk Sohn, Jong Shin Woo, Jin Won Kim, Soon Jun Hong, Jung Hyun Choi, Jung‐Won Suh, Jae‐Bin Seo, Joon‐Hyung Doh, Jung‐Woo Son, Jae‐Hyeong Park, Ju‐Hee Lee, Young Joon Hong, Jung Ho Heo, Jinho Shin, Seok‐Min
    The Journal of Clinical Hypertension.2024; 26(3): 262.     CrossRef
  • Anti-hyperglycemic, anti-hyperlipidemic, and anti-inflammatory effect of the drug Guggulutiktaka ghrita on high-fat diet-induced obese rats
    Samreen M. Sheik, Pugazhandhi Bakthavatchalam, Revathi P. Shenoy, Basavaraj S. Hadapad, Deepak Nayak M, Monalisa Biswas, Varashree Bolar Suryakanth
    Journal of Ayurveda and Integrative Medicine.2022; 13(3): 100583.     CrossRef
  • The challenge of reducing residual cardiovascular risk in patients with chronic kidney disease
    Stefan Mark Nidorf
    European Heart Journal.2022; 43(46): 4845.     CrossRef
  • Diabetic Kidney Disease in Older People with Type 2 Diabetes Mellitus: Improving Prevention and Treatment Options
    Ahmed H. Abdelhafiz
    Drugs & Aging.2020; 37(8): 567.     CrossRef
  • Intracellular Mechanism of Rosuvastatin-Induced Decrease in Mature hERG Protein Expression on Membrane
    Pan-Feng Feng, Bo Zhang, Lei Zhao, Qing Fang, Yan Liu, Jun-Nan Wang, Xue-Qi Xu, Hui Xue, Yang Li, Cai-Chuan Yan, Xin Zhao, Bao-Xin Li
    Molecular Pharmaceutics.2019; 16(4): 1477.     CrossRef
  • The problem of safety of lipid-lowering therapy
    M V. Zykov
    Kardiologiia.2019; 59(5S): 13.     CrossRef
  • Regional evidence and international recommendations to guide lipid management in Asian patients with type 2 diabetes with special reference to renal dysfunction
    Titus WL Lau, Kevin E.K. Tan, Jason C.J. Choo, Tsun‐Gun Ng, Subramaniam Tavintharan, Juliana C.N. Chan
    Journal of Diabetes.2018; 10(3): 200.     CrossRef
  • Lipids: a personal view of the past decade
    Niki Katsiki, Dimitri P Mikhailidis
    Hormones.2018; 17(4): 461.     CrossRef
Close layer
Clinical Study
Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study
Byung Sub Moon, Jongho Kim, Ji Hyun Kim, Young Youl Hyun, Se Eun Park, Hyung-Geun Oh, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Kyu-Beck Lee, Hyang Kim, Sung-Woo Park, Eun-Jung Rhee
Endocrinol Metab. 2016;31(3):402-409.   Published online August 26, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.3.402
  • 3,794 View
  • 32 Download
  • 4 Web of Science
  • 4 Crossref
AbstractAbstract PDFPubReader   
Background

The purpose of this study was to investigate the relationship between statin eligibility and the degree of renal dysfunction using the Adult Treatment Panel (ATP) III and the American College of Cardiology (ACC)/American Heart Association (AHA) guidelines in Korean adults.

Methods

Renal function was assessed in 18,746 participants of the Kangbuk Samsung Health Study from January 2011 to December 2012. Subjects were divided into three groups according to estimated glomerular filtration rate (eGFR): stage 1, eGFR ≥90 mL/min/1.73 m2; stage 2, eGFR 60 to 89 mL/min/1.73 m2; and stages 3 to 5, eGFR <60 mL/min/1.73 m2. Statin eligibility in these groups was determined using the ATP III and ACC/AHA guidelines, and the risk for 10-year atherosclerotic cardiovascular disease (ASCVD) was calculated using the Framingham Risk Score (FRS) and Pooled Cohort Equation (PCE).

Results

There were 3,546 (18.9%) and 4,048 (21.5%) statin-eligible subjects according to ATP III and ACC/AHA guidelines, respectively. The proportion of statin-eligible subjects increased as renal function deteriorated. Statin eligibility by the ACC/AHA guidelines showed better agreement with the Kidney Disease Improving Global Outcomes (KDIGO) recommendations compared to the ATP III guidelines in subjects with stage 3 to 5 chronic kidney disease (CKD) (κ value, 0.689 vs. 0.531). When the 10-year ASCVD risk was assessed using the FRS and PCE, the mean risk calculated by both equations significantly increased as renal function declined.

Conclusions

The proportion of statin-eligible subjects significantly increased according to worsening renal function in this Korean cohort. ACC/AHA guideline showed better agreement for statin eligibility with that recommended by KDIGO guideline compared to ATP III in subjects with CKD.

Citations

Citations to this article as recorded by  
  • Association between atherosclerotic cardiovascular diseases risk and renal outcome in patients with type 2 diabetes mellitus
    Honghong Ren, Lijun Zhao, Yutong Zou, Yiting Wang, Junlin Zhang, Yucheng Wu, Rui Zhang, Tingli Wang, Jiali Wang, Yitao Zhu, Ruikun Guo, Huan Xu, Lin Li, Mark E. Cooper, Fang Liu
    Renal Failure.2021; 43(1): 477.     CrossRef
  • Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea
    Seo Yeon Baik, Hyunah Kim, So Jung Yang, Tong Min Kim, Seung-Hwan Lee, Jae Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim
    Frontiers of Medicine.2019; 13(6): 713.     CrossRef
  • Analysis and comparison of the cost-effectiveness of statins according to the baseline low-density lipoprotein cholesterol level in Korea
    Y. J. Jeong, H. Kim, S. J. Baik, T. M. Kim, S. J. Yang, S.-H. Lee, J.-H. Cho, H. Lee, H. W. Yim, I. Y. Choi, K.-H. Yoon, H.-S. Kim
    Journal of Clinical Pharmacy and Therapeutics.2017; 42(3): 292.     CrossRef
  • Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
    Eugene Han, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Beom Seok Kim, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
    Endocrinology and Metabolism.2017; 32(2): 274.     CrossRef
Close layer
Review Article
Obesity and Metabolism
Current Challenges in Diabetic Nephropathy: Early Diagnosis and Ways to Improve Outcomes
Sang Soo Kim, Jong Ho Kim, In Joo Kim
Endocrinol Metab. 2016;31(2):245-253.   Published online May 27, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.2.245
  • 5,917 View
  • 90 Download
  • 50 Web of Science
  • 44 Crossref
AbstractAbstract PDFPubReader   

Diabetes is often associated with chronic kidney disease (CKD) and is the primary cause of kidney failure in half of patients who receive dialysis therapy. Given the increasing prevalence of diabetes and its high morbidity and mortality, diabetic nephropathy is a serious drawback in individual patients and a tremendous socioeconomic burden on society. Despite growing concern for the management of diabetic nephropathy, the prevalence of CKD with diabetes is the same today as it was 20 years ago. The current strategy to manage diabetic nephropathy, including the control of hyperglycemia, dyslipidemia, and blood pressure and the wide-spread use of renin-angiotensin-aldosterone system inhibitors, is well established to be beneficial in the early stages of diabetic nephropathy. However, the effects are uncertain in patients with relatively progressed CKD. Therefore, early diagnosis or risk verification is extremely important in order to reduce the individual and socioeconomic burdens associated with diabetic nephropathy by providing appropriate management to prevent the development and progression of this condition. This review focuses on recent research and guidelines regarding risk assessment, advances in medical treatment, and challenges of and future treatments for diabetic nephropathy.

Citations

Citations to this article as recorded by  
  • The Role of Angiotensin-Converting Enzyme (ACE) Polymorphisms in the Risk of Development and Treatment of Diabetic Nephropathy
    Magdalena Król-Kulikowska, Nikita Abramenko, Milan Jakubek, Mirosław Banasik, Marta Kepinska
    Journal of Clinical Medicine.2024; 13(4): 995.     CrossRef
  • Gestione perioperatoria del paziente diabetico adulto
    M. Raucoules-Aimé, T. Thierry Nessan Ouattara
    EMC - Anestesia-Rianimazione.2023; 28(1): 1.     CrossRef
  • Pyruvate Kinase M2: A New Biomarker for the Early Detection of Diabetes-Induced Nephropathy
    Yeon Su Park, Joo Hee Han, Jae Hyeon Park, Ji Soo Choi, Seung Hyeon Kim, Hyung Sik Kim
    International Journal of Molecular Sciences.2023; 24(3): 2683.     CrossRef
  • Tratamiento perioperatorio del paciente diabético adulto
    M. Raucoules-Aimé, T. Thierry Nessan Ouattara
    EMC - Anestesia-Reanimación.2023; 49(1): 1.     CrossRef
  • Renal Protection of Mineralocorticoid Receptor Antagonist, Finerenone, in Diabetic Kidney Disease
    Dong-Lim Kim, Seung-Eun Lee, Nan Hee Kim
    Endocrinology and Metabolism.2023; 38(1): 43.     CrossRef
  • The role of tubulointerstitial markers in differential diagnosis and prognosis in patients with type 2 diabetes and biopsy proven diabetic kidney disease
    Xijian Wang, Liang Ren, Ying Huang, Zhengang Feng, Guangdi Zhang, Houyong Dai
    Clinica Chimica Acta.2023; 547: 117448.     CrossRef
  • Network pharmacology and molecular docking technology-based predictive study of the active ingredients and potential targets of rhubarb for the treatment of diabetic nephropathy
    Shaojie Fu, Yena Zhou, Cong Hu, Zhonggao Xu, Jie Hou
    BMC Complementary Medicine and Therapies.2022;[Epub]     CrossRef
  • Acrolein plays a culprit role in the pathogenesis of diabetic nephropathy in vitro and in vivo
    Zhen-Jie Tong, Chin-Wei Kuo, Po-Cheng Yen, Chih-Ching Lin, Ming-Tsun Tsai, Shing-Hwa Lu, Yi-Ping Chang, Wen-Sheng Liu, Han-Hsing Tsou, Hsiao-Wei Cheng, Hsiang-Tsui Wang
    European Journal of Endocrinology.2022; 187(4): 579.     CrossRef
  • Probiotics ameliorates glycemic control of patients with diabetic nephropathy: A randomized clinical study
    Hongyang Jiang, Yan Zhang, Dongyan Xu, Qing Wang
    Journal of Clinical Laboratory Analysis.2021;[Epub]     CrossRef
  • Blood Oxygen Level-Dependent (BOLD) MRI in Glomerular Disease
    Daniel R. Nemirovsky, Puneet Gupta, Sophia Hu, Raymond Wong, Avnesh S. Thakor
    Transplantology.2021; 2(2): 109.     CrossRef
  • Amelioration of STZ-induced nephropathy in diabetic rats by saffron hydro alcoholic extract
    Jamal Amri, Mona Alaee, Seyed Amirhossein Latifi, Abbas Alimoradian, Mehdi Salehi
    Hormone Molecular Biology and Clinical Investigation.2021; 42(4): 411.     CrossRef
  • Exosomes: Biomarkers and Therapeutic Targets of Diabetic Vascular Complications
    Anqi Chen, Hailing Wang, Ying Su, Chunlin Zhang, Yanmei Qiu, Yifan Zhou, Yan Wan, Bo Hu, Yanan Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Sodium-glucose cotransporter 2 inhibitors benefit to kidney and cardiovascular outcomes for patients with type 2 diabetes mellitus and chronic kidney disease 3b-4: A systematic review and meta-analysis of randomized clinical trials
    Haiyan Cao, Youxia Liu, Zhixia Tian, Yuhang Lian, Junya Jia, Ming Liu, Dong Li
    Diabetes Research and Clinical Practice.2021; 180: 109033.     CrossRef
  • Proteinuria as a significant predictive factor for the progression of carotid artery atherosclerosis in non-albuminuric type 2 diabetes
    Young-eun Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-soo Cha, Byung-Wan Lee
    Diabetes Research and Clinical Practice.2021; 181: 109082.     CrossRef
  • The Role of Mesenchymal Stromal Cells-Derived Small Extracellular Vesicles in Diabetes and Its Chronic Complications
    Fu-Xing-Zi Li, Xiao Lin, Feng Xu, Su-Kang Shan, Bei Guo, Li-Min Lei, Ming-Hui Zheng, Yi Wang, Qiu-Shuang Xu, Ling-Qing Yuan
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects
    Zhonghua Dong, Sajid Iqbal, Zhongxi Zhao
    AAPS PharmSciTech.2020;[Epub]     CrossRef
  • Carbon dots as fluorescent nanoprobe for the determination of N-acetyl-β-d-glucosaminidase activity
    Jimei Ma, Heng Zhang, Fangfang Peng, Xiaoqing Yang, Zi-Long Li, Linhao Sun, Hong Jiang
    Analytica Chimica Acta.2020; 1101: 129.     CrossRef
  • Coffee Consumption is Associated with a Decreased Risk of Incident Chronic Kidney Disease: A Systematic Review and Meta-analysis of Cohort Studies
    Thatsaphan Srithongkul, Patompong Ungprasert
    European Journal of Internal Medicine.2020; 77: 111.     CrossRef
  • Understanding molecular upsets in diabetic nephropathy to identify novel targets and treatment opportunities
    Nidhi Raval, Akshant Kumawat, Dnyaneshwar Kalyane, Kiran Kalia, Rakesh K. Tekade
    Drug Discovery Today.2020; 25(5): 862.     CrossRef
  • A meta-analysis of serum Hcy in diagnosis of diabetic nephropathy
    Xiaoling Zhou, Aijie Shi, Xiao Zhou
    Pteridines.2020; 31(1): 1.     CrossRef
  • Link between ACE I/D gene polymorphism and dyslipidemia in diabetic nephropathy: A case-control study from Hyderabad, India
    UmmeNajiya Mahwish, KamakshiChaithri Ponnaluri, Babi Heera, SatishReddy Alavala, KRudrama Devi, SreeBhushan Raju, GSuman Latha, Parveen Jahan
    Indian Journal of Nephrology.2020; 30(2): 77.     CrossRef
  • Assessment of urinary NGAL for differential diagnosis and progression of diabetic kidney disease
    Suyan Duan, Jiajia Chen, Lin Wu, Guangyan Nie, Lianqin Sun, Chengning Zhang, Zhimin Huang, Changying Xing, Bo Zhang, Yanggang Yuan
    Journal of Diabetes and its Complications.2020; 34(10): 107665.     CrossRef
  • Urinary proteins detected using modern proteomics intervene in early type 2 diabetic kidney disease – a pilot study
    Alina Golea-Secara, Cristian Munteanu, Mirela Sarbu, Octavian M Cretu, Silvia Velciov, Adrian Vlad, Flaviu Bob, Florica Gadalean, Cristina Gluhovschi, Oana Milas, Anca Simulescu, Maria Mogos-Stefan, Mihaela Patruica, Ligia Petrica, Alina D Zamfir
    Biomarkers in Medicine.2020; 14(16): 1521.     CrossRef
  • Efficacy and safety of Shenkang injection as adjuvant therapy in patients with diabetic nephropathy
    Yanping Wang, Mingzhu Li, Chenyun Li, Sheng Xu, Jiangfeng Wu, Gaochuan Zhang, Yuanyuan Cai
    Medicine.2020; 99(52): e23821.     CrossRef
  • A Nucleoside/Nucleobase-Rich Extract from Cordyceps Sinensis Inhibits the Epithelial–Mesenchymal Transition and Protects against Renal Fibrosis in Diabetic Nephropathy
    Zhonghua Dong, Yueyue Sun, Guangwei Wei, Siying Li, Zhongxi Zhao
    Molecules.2019; 24(22): 4119.     CrossRef
  • Lack of Association between Past Helicobacter pylori Infection and Diabetes: A Two-Cohort Study
    Jeung Hui Pyo, Hyuk Lee, Sung Chul Choi, Soo Jin Cho, Yoon-Ho Choi, Yang Won Min, Byung-Hoon Min, Jun Haeng Lee, Heejin Yoo, Kyunga Kim, Jae J. Kim
    Nutrients.2019; 11(8): 1874.     CrossRef
  • Serum Homocysteine, cystatin C as Biomarkers for Progression of Diabetic Nephropathy
    Weihai Xu, Suhua Tang, Meijuan Xiang, Jianyun Peng
    Pteridines.2019; 30(1): 183.     CrossRef
  • Serum leptin in diabetic nephropathy male patients from Gaza Strip
    Maged M. Yassin, Ayman M. AbuMustafa, Mohamed M. Yassin
    Diabetes & Metabolic Syndrome: Clinical Research & Reviews.2019; 13(2): 1245.     CrossRef
  • Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Renal Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    Jae Hyun Bae, Eun-Gee Park, Sunhee Kim, Sin Gon Kim, Seokyung Hahn, Nam Hoon Kim
    Scientific Reports.2019;[Epub]     CrossRef
  • Association between nonalbumin proteinuria and renal tubular damage of N-acetyl-β-d-glucosaminidase and its clinical relevance in patients with type 2 diabetes without albuminuria
    Eugene Han, Mi-Kyung Kim, Yong-ho Lee, Hye Soon Kim, Byung-Wan Lee
    Journal of Diabetes and its Complications.2019; 33(3): 255.     CrossRef
  • Supplementation of Abelmoschus manihot Ameliorates Diabetic Nephropathy and Hepatic Steatosis by Activating Autophagy in Mice
    Hwajin Kim, Theodomir Dusabimana, So Kim, Jihyun Je, Kyuho Jeong, Min Kang, Kye Cho, Hye Kim, Sang Park
    Nutrients.2018; 10(11): 1703.     CrossRef
  • Perioperative management of adult diabetic patients. Preoperative period
    Gaëlle Cheisson, Sophie Jacqueminet, Emmanuel Cosson, Carole Ichai, Anne-Marie Leguerrier, Bogdan Nicolescu-Catargi, Alexandre Ouattara, Igor Tauveron, Paul Valensi, Dan Benhamou
    Anaesthesia Critical Care & Pain Medicine.2018; 37: S9.     CrossRef
  • Practical management of diabetes patients before, during and after surgery: A joint French diabetology and anaesthesiology position statement
    E. Cosson, B. Catargi, G. Cheisson, S. Jacqueminet, C. Ichai, A.-M. Leguerrier, A. Ouattara, I. Tauveron, E. Bismuth, D. Benhamou, P. Valensi
    Diabetes & Metabolism.2018; 44(3): 200.     CrossRef
  • MicroRNA‐326‐3p ameliorates high glucose and ox‐LDL‐IC‐ induced fibrotic injury in renal mesangial cells by targeting FcγRIII
    Yiting Wang, Rui Zhang, Junlin Zhang, Fang Liu
    Nephrology.2018; 23(11): 1031.     CrossRef
  • Urinary Extracellular Vesicle
    Wei-Cheng Xu, Ge Qian, Ai-Qun Liu, Yong-Qiang Li, He-Qun Zou
    Chinese Medical Journal.2018; 131(11): 1357.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Comparison between Atorvastatin and Rosuvastatin in Renal Function Decline among Patients with Diabetes
    Eugene Han, Gyuri Kim, Ji-Yeon Lee, Yong-ho Lee, Beom Seok Kim, Byung-Wan Lee, Bong-Soo Cha, Eun Seok Kang
    Endocrinology and Metabolism.2017; 32(2): 274.     CrossRef
  • WITHDRAWN: Salvianolate attenuates renal fibrosis in rat models of diabetic nephropathy by inhibiting inflammation and oxidative stress mechanisms
    Chongxiang Xiong, Jianrao Lu, Xinhua Wang, Monica V. Masucci
    Biochemical and Biophysical Research Communications.2017;[Epub]     CrossRef
  • Diffusion tensor imaging of the renal cortex in diabetic patients: correlation with urinary and serum biomarkers
    Ahmed Abdel Khalek Abdel Razek, Mohammad Alsayed Abd Alhamid Al-Adlany, Alhadidy Mohammed Alhadidy, Mohammed Ali Atwa, Naglaa Elsayed Abass Abdou
    Abdominal Radiology.2017; 42(5): 1493.     CrossRef
  • Texte 2 : période préopératoire
    Gaëlle Cheisson, Sophie Jacqueminet, Emmanuel Cosson, Carole Ichai, Anne-Marie Leguerrier, Bogdan Nicolescu-Catargi, Alexandre Ouattara, Igor Tauveron, Paul Valensi, Dan Benhamou
    Anesthésie & Réanimation.2017; 3(3): 218.     CrossRef
  • Global Cardiovascular and Renal Outcomes of Reduced GFR
    Bernadette Thomas, Kunihiro Matsushita, Kalkidan Hassen Abate, Ziyad Al-Aly, Johan Ärnlöv, Kei Asayama, Robert Atkins, Alaa Badawi, Shoshana H. Ballew, Amitava Banerjee, Lars Barregård, Elizabeth Barrett-Connor, Sanjay Basu, Aminu K. Bello, Isabela Bensen
    Journal of the American Society of Nephrology.2017; 28(7): 2167.     CrossRef
  • Salvia miltiorrhiza Lipophilic Fraction Attenuates Oxidative Stress in Diabetic Nephropathy through Activation of Nuclear Factor Erythroid 2-Related Factor 2
    Lin An, Mei Zhou, Faiz M. M. T. Marikar, Xue-Wen Hu, Qiu-Yun Miao, Ping Li, Jun Chen
    The American Journal of Chinese Medicine.2017; 45(07): 1441.     CrossRef
  • Addition of nonalbumin proteinuria to albuminuria improves prediction of type 2 diabetic nephropathy progression
    Jong Ho Kim, Seo Young Oh, Eun Heui Kim, Min Jin Lee, Yun Kyung Jeon, Bo Hyun Kim, Jin Mi Kim, Yong Ki Kim, Sang Soo Kim, In Joo Kim
    Diabetology & Metabolic Syndrome.2017;[Epub]     CrossRef
  • Reversal of Early Diabetic Nephropathy by Islet Transplantation under the Kidney Capsule in a Rat Model
    Yunqiang He, Ziqiang Xu, Mingshi Zhou, Minmin Wu, Xuehai Chen, Silu Wang, Kaiyan Qiu, Yong Cai, Hongxing Fu, Bicheng Chen, Mengtao Zhou
    Journal of Diabetes Research.2016; 2016: 1.     CrossRef
Close layer
Original Article
Age Is the Strongest Effector for the Relationship between Estimated Glomerular Filtration Rate and Coronary Artery Calcification in Apparently Healthy Korean Adults
Hyun Beom Chae, Shin Yeoung Lee, Nam Hee Kim, Ki Joong Han, Tae Hoon Lee, Choel Min Jang, Kyung Mo Yoo, Hae Jung Park, Min Kyung Lee, Won Seon Jeon, Se Eun Park, Heui-Soo Moon, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Sung-Woo Park, Eun-Jung Rhee
Endocrinol Metab. 2014;29(3):312-319.   Published online September 25, 2014
DOI: https://doi.org/10.3803/EnM.2014.29.3.312
  • 3,616 View
  • 33 Download
  • 6 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   
Background

Chronic kidney disease (CKD) is considered one of the most common risk factors for cardiovascular disease. Coronary artery calcification (CAC) is a potential mechanism that explains the association between renal function and cardiovascular mortality. We aimed to evaluate the association between renal function and CAC in apparently healthy Korean subjects.

Methods

A total of 23,617 participants in a health-screening program at Kangbuk Samsung Hospital were included in the study. Estimated glomerular filtration rate (eGFR) was assessed using the Cockcroft-Gault equation. Coronary artery calcium score (CACS) was measured via multidetector computed tomography. Subjects were divided into three groups according to the CKD Staging system with eGFR grade: stage 1, eGFR ≥90 mL/min/1.73 m2; stage 2, eGFR 60 to 89 mL/min/1.73 m2; and stage 3, eGFR 30 to 59 mL/min/1.73 m2.

Results

The mean age of the participants was 41.4 years and the mean eGFR was 103.6±21.7 mL/min/1.73 m2. Hypertension and diabetes were noted in 43.7% and 5.5% of the participants, respectively. eGFR showed a weakly negative but significant association with CACS in bivariate correlation analysis (r=-0.076, P<0.01). Mean CACS significantly increased from CKD stage 1 to 3. The proportion of subjects who had CAC significantly increased from CKD stage 1 to 3. Although the odds ratio for CAC significantly increased from stage 1 to 3 after adjustment for confounding factors, this significance was reversed when age was included in the model.

Conclusion

In early CKD, renal function negatively correlated with the degree of CAC in Korean subjects. Age was the strongest effector for this association.

Citations

Citations to this article as recorded by  
  • Coronary artery calcium and risk of chronic kidney disease in young and middle-aged adults
    Yejin Kim, Jeonggyu Kang, Yoosoo Chang, Young Youl Hyun, Kyu-Beck Lee, Hocheol Shin, Sarah H Wild, Christopher D Byrne, Seungho Ryu
    Nephrology Dialysis Transplantation.2023; 38(6): 1439.     CrossRef
  • New Model for Predicting the Presence of Coronary Artery Calcification
    Samel Park, Min Hong, HwaMin Lee, Nam-jun Cho, Eun-Young Lee, Won-Young Lee, Eun-Jung Rhee, Hyo-Wook Gil
    Journal of Clinical Medicine.2021; 10(3): 457.     CrossRef
  • Long-term effects of various types of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on changes in glomerular filtration rate in Korea
    Seo Yeon Baik, Hyunah Kim, So Jung Yang, Tong Min Kim, Seung-Hwan Lee, Jae Hyoung Cho, Hyunyong Lee, Hyeon Woo Yim, Kun-Ho Yoon, Hun-Sung Kim
    Frontiers of Medicine.2019; 13(6): 713.     CrossRef
  • Chronic kidney disease and coronary artery calcification in the Brazilian Longitudinal Study of Adult Health (ELSA‐Brasil)
    Cheng Suh‐Chiou, Rosa M. Moysés, Marcio S. Bittencourt, Isabela M. Bensenor, Paulo A. Lotufo
    Clinical Cardiology.2017; 40(12): 1309.     CrossRef
  • Eligibility for Statin Treatment in Korean Subjects with Reduced Renal Function: An Observational Study
    Byung Sub Moon, Jongho Kim, Ji Hyun Kim, Young Youl Hyun, Se Eun Park, Hyung-Geun Oh, Cheol-Young Park, Won-Young Lee, Ki-Won Oh, Kyu-Beck Lee, Hyang Kim, Sung-Woo Park, Eun-Jung Rhee
    Endocrinology and Metabolism.2016; 31(3): 402.     CrossRef
  • Articles in 'Endocrinology and Metabolism' in 2014
    Won-Young Lee
    Endocrinology and Metabolism.2015; 30(1): 47.     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism